1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
(
- Contribution to journal › Article
-
Mark
Impact on follow-up strategies in patients with primary sclerosing cholangitis
(
- Contribution to journal › Article
- 2022
-
Mark
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
(
- Contribution to journal › Article
- 2021
-
Mark
The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients
(
- Contribution to journal › Article
-
Mark
Assessment of lifestyle factors helps to identify liver fibrosis due to non-alcoholic fatty liver disease in obesity
(
- Contribution to journal › Article
- 2020
-
Mark
MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans
(
- Contribution to journal › Letter
-
Mark
Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease
(
- Contribution to journal › Article
- 2017
-
Mark
Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD
(
- Contribution to journal › Article
- 2016
-
Mark
The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans
(
- Contribution to journal › Letter
- 2014
-
Mark
A population-based study on the prevalence of NASH using scores validated against liver histology.
(
- Contribution to journal › Article